TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
3SBio ( (HK:1530) ) just unveiled an update.
3SBio Inc. announced that its anti-VEGF/PD-1 bispecific antibody, known as 707 Injection, has been granted Breakthrough Therapy Designation by China’s National Medical Products Administration for the first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer. This designation will accelerate the drug’s development and potential market launch, reflecting 3SBio’s strengthened position in the oncology sector and its commitment to advancing cancer treatment options.
More about 3SBio
3SBio Inc. is a biotechnology company focused on developing and manufacturing biopharmaceutical products. The company specializes in innovative therapies, particularly in the field of oncology, with a market focus on China and international markets.
YTD Price Performance: 25.97%
Technical Sentiment Signal: Sell
Current Market Cap: $3.86B
See more insights into 1530 stock on TipRanks’ Stock Analysis page.